sellWeak10b5-1 plan
Hopkinson Craig C. sold $3.2M of ALKS
EVP R&D, Chief Medical Officer at Alkermes plc.. 100,918 shares at an average of $32.05, traded Jan 30, 2025, filed Jan 31, 2025.
Warning score
25Value
$3.2M
100,918 shares
Holdings after
44,290
-69% from before
From 52-week low
+24%
low $25.70, close $31.91
From 52-week high
0%
high $31.91, as of Jan 30, 2025
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price, last year
Rows in this filing
Every transaction in Form 4 0001127602-25-002645, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 30, 2025 | MOption exercise Ordinary Shares10b5-1 | +29,156 | $20.03 | $584k | 76,732 | Jan 31, 2025 |
| Jan 30, 2025 | MOption exercise Ordinary Shares10b5-1 | +26,589 | $19.34 | $514k | 103,321 | Jan 31, 2025 |
| Jan 30, 2025 | MOption exercise Ordinary Shares10b5-1 | +23,542 | $24.59 | $579k | 126,863 | Jan 31, 2025 |
| Jan 30, 2025 | MOption exercise Ordinary Shares10b5-1 | +18,345 | $26.82 | $492k | 145,208 | Jan 31, 2025 |
| Jan 30, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -100,918 | $32.05 | $3.2M | 44,290 | Jan 31, 2025 |
| Jan 30, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -29,156 | $0.00 | $0 | 87,566 | Jan 31, 2025 |
| Jan 30, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -26,589 | $0.00 | $0 | 161,734 | Jan 31, 2025 |
| Jan 30, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -23,542 | $0.00 | $0 | 106,758 | Jan 31, 2025 |
| Jan 30, 2025 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -18,345 | $0.00 | $0 | 92,271 | Jan 31, 2025 |
Related signals
Other insiders at Alkermes plc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 0Weak | sell10b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $66k | 1,938 | |
| 9Weak | sell 210b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $132k | 3,743 | |
| 0Weak | sell 210b5-1 | ALKS Alkermes plc. | Parisi Samuel Joseph VP, Finance (Interim PAO) | $47k | 1,327 | |
| 33Weak | sell 210b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $12M | 349,340 | |
| 9Weak | sell 310b5-1 | ALKS Alkermes plc. | LAURENCIN CATO T director | $86k | 2,691 | |
| 40Moderate | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $2.0M | 61,151 | |
| 29Weak | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $290k | 9,221 | |
| 32Weak | sell 310b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $442k | 14,349 | |
| 21Weak | sell 310b5-1 | ALKS Alkermes plc. | Nichols Christian Todd SVP, Chief Commercial Officer | $152k | 5,208 | |
| 15Weak | sell10b5-1 | ALKS Alkermes plc. | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $1.8M | 58,996 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.